This report provides a concise update on the full landscape of biomedical interventions: including PrEP products in the market and next-gen products in the pipeline—multipurpose products (MPTs), vaccines and broadly neutralizing antibodies.
Biomedical HIV Prevention Research in 2022 and Beyond
New Products Are Needed But a New Paradigm is Essential
With all the talk about new HIV prevention products such as the dapivirine vaginal ring or injectable cabotegravir for PrEP (CAB for PrEP), what’s little understood is how to match proven products with the programs, policies and political will needed to get them to the people who need them. This episode explores the shifting landscape in HIV prevention and how this moment gives the world a chance to finally reimagine how to DELIVER prevention.
We go from big picture to grass roots, and dig into what it’s going to take to reach global targets. There’s a new road map out from the Global HIV Prevention Coalition with a big vision and a new target of less than 370,000 new infections by 2025. And PEPFAR’s new Strategic Direction talks about a target for ending the epidemic as a public health threat by 2030, but how are we going to get there?
This episode brings three perspectives together:
PEPFAR Ambassador Dr. John Nkengasong describes a model to scale up prevention in 5 countries and show impact in 1-2 years.
Executive Director of HEPS-Uganda, and former AVAC Advocacy Fellow, Kenneth Mwehonge talks about the commitments needed from a range of stakeholders to bring the Coalition’s new roadmap to life, and hit 2030 targets.
Lilian Benjamin Mwakyosi, the Executive Director of DARE and former AVAC Advocacy Fellow, talks about the day-to-day obstacles faced by young women who need prevention, what’s working now and what needs to change in HIV prevention programs.
Highlights
- Listen to the ambassador’s appeal for an aggressive strategy to scale up combination prevention, including injectable cabotegravir for PrEP.
Resources
- The 2025 new roadmap out from UNAIDS and the Global HIV Prevention Coalition
- PEPFAR’s New Strategic Direction
- UN shift on HIV prevention raises hope we can end AIDS by 2030—now we need to turn words into action – Daily Maverick
- HIV prevention for the next decade: Appropriate, person-centred, prioritised, effective, combination prevention – PLOS
- More about combination prevention at AVAC.org
PrEPWatch
PrEPWatch is designed to be a clearinghouse for information on PrEP research (ongoing and completed; clinical trials and demonstration projects), data, additional research, cost, access and advocacy efforts across the globe.
Px Wire July-September 2022, Vol. 12, No. 2
PrEP Tracker data, preparing for new products, the HIV prevention pipeline and our prevention playlist. All that and more in the latest issue of Px Wire.
PEP Needs Some Pep! Addressing PEP Neglect in HIV Prevention Research, Programming and Uptake
Thursday, November 3, 2022
During this webinar, experts and advocates addressed why PEP has been long neglected in HIV prevention research, programming, and uptake.
Featuring Dr. James Ayieko, Dr. Julie Fox, Dr. Ken Mayer, Dr, Catherine Koss, Njambi Njuguna and Ace Robinson
Cost of Goods Sold (COGS) Analyses
FAQ Debrief
This FAQ explains the use of Cost of Good Sold Analyses (COGS) and how they inform planning for product introduction.
RINGing the Bell for Choice: Actions and Solutions on Dapivirine Ring Access
Thursday, September 22, 2022
Hear the latest updates from African advocates leading the advocacy for access to the dapivirine ring. Plus tune in for the Population Council’s plans for moving the ring forward on multiple fronts, from roll-out of the monthly ring to research around the 3-month ring and multipurpose ring.
Px Wire April-June 2022, Vol. 12, No. 1
Newly relaunched, PxWire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research and development, implementation and advocacy. Download for a quick look at where we are in HIV prevention.
A Plan for Accelerating Access and Introduction of Injectable CAB for PrEP (Summary)
AVAC published Translating Scientific Advance into Public Health Impact: A Plan for Accelerating Access and Introduction of Injectable CAB for PrEP to provide a comprehensive view of all the moving parts and identify specific priority actions and actors responsible for ensuring time is not wasted and opportunity not squandered in introducing injectable cabotegravir for PrEP. ViiV, policy makers, normative agencies, donors, program implementers, researchers, generic manufacturers, civil society, advocates and communities each have critical roles to play in the coming months, and this summary provides an overview of the plan.
AVAC Comments to FDA in Support of PrEP Approval
Comments delivered to the FDA’s Antiviral Drugs Advisory Committee (AVDAC) Meeting by Mitchell Warren, Executive Director, AVAC.